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Major depressive disorder (MDD) is a mood disorder of multifactorial origin affecting
millions of people worldwide. The alarming estimated rates of prevalence and relapse
make it a global public health concern. Moreover, the current setback of available
antidepressants in the clinical setting is discouraging. Therefore, efforts to eradicate
depression should be directed towards understanding the pathomechanisms involved
in the hope of finding cost-effective treatment alternatives. The pathophysiology of MDD
comprises the breakdown of different pathways, including the hypothalamus-pituitary-
adrenal (HPA) axis, the glutamatergic system, and monoaminergic neurotransmission,
affecting cognition and emotional behavior. Inflammatory cytokines have been postulated
to be the possible link and culprit in the disruption of these systems. In addition,
evidence from different studies suggests that impairment of glial functions appears
to be a major contributor as well. Thus, the intricate role between glia, namely
microglia and astrocytes, and the central nervous system’s (CNSs) immune response
is briefly discussed, highlighting the kynurenine pathway as a pivotal player. Moreover,
evaluations of different treatment strategies targeting the inflammatory response are
considered. The immuno-modulatory properties of vitamin D receptor (VDR) suggest
that vitamin D is an attractive and plausible candidate in spite of controversial
findings. Further research investigating the role of VDR in mood disorders is
warranted.
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Introduction
Depression is a common neuropsychiatric disorder constituting one of the leading
causes of disability worldwide, estimated to affect 350 million people, and projected
to be the leading cause of disease burden by 2030 (World-Health-Organization, 2008;
World-Federation-for-Mental-Health, 2012). The comorbid state of depression together with
a number of other physical and psychiatric disorders results in increased disability and
mortality rates. Among some of the most frequently associated disorders are cardiovascular
disease, cancer, diabetes, obesity, attention deficit hyperactivity disorder, and Alzheimer’s
disease (Schillani et al., 2012; Hannon et al., 2013; Mavrides and Nemeroff, 2013; Wuwongse
et al., 2013; Di Trani et al., 2014).
Although major depressive disorder (MDD) has been extensively studied, rates of depression
have not decreased over the past decades. According to a review comparing cases of
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mental disorders between 2004 and 2010 in the European Union,
rates in this period remained more or less stable with the
increase in better detection and health care systems. However,
in a previous study the prevalence of persons affected each
year was estimated to be 38.2%, depression being the second
most prevalent form of mental disorders (6.9%; Wittchen et al.,
2011). Moreover, with the currently prescribed pharmacological
agents, relapse rates are as high as 50%, only one-third of
patients achieving complete remission. Therefore, there is a clear
necessity to increase the amount of research investigating the
molecular mechanisms pertaining depression. The aim of this
review is to connect the different pathophysiological pathways of
depression in an effort to find suitable treatments.
Major Depressive Disorder
MDD along with bipolar disorder are categorized under mood
disorders, also referred to as affective disorders. MDD is a
condition characterized by one or more depressive episodes
along with pathophysiological changes in the brain (Muller
and Schwarz, 2007). These depressive episodes appear without
a history of manic or hypomanic episodes, as in the case
of bipolar disorder. Typical symptoms include low mood,
anhedonia, appetite alterations, sleep disturbances, fatigue, poor
concentration, and feelings of worthlessness, among others
(World-Federation-for-Mental-Health, 2012). Moreover, MDD
is attributed as a risk factor for suicide attempts and drug abuse
(Davis et al., 2008). Furthermore, depressive episodes are often
recurrent, incrementing individual and social burden (World-
Federation-for-Mental-Health, 2012).
Characteristic pathophysiological hallmark features include
monoamine depletion, glucocorticoid receptor (GR) resistance,
and excess of glutamate, corticotrophin-releasing hormone and
cortisol levels, therefore compromising the monoaminergic and
glutamatergic neurotransmission along with the hypothalamus-
pituitary-adrenal (HPA) axis activity (Muller and Schwarz,
2007).
The onset of MDD is complex and can be triggered by several
different factors. While genetic factors have been estimated
to contribute 30–40% of the etiology of MDD, the remaining
factors are accounted for by environmental risk factors. Negative
traumatic events during lifetime (e.g., child abuse, parental
divorce, death of a loved one, etc.) can lead to MDD. However,
this depends on the genetic susceptibility, gender, family history,
and personality traits of the person affected (Heim and Binder,
2012). Family risk factors are estimated to increase its incidence
two to three times (Wilde et al., 2014). Development of MDD
is suggested to be the outcome of the interplay between both
genetic and environmental risk factors rather than the result of
one factor. For instance, it was demonstrated in one study that
interactions between experiences of childhood abuse and genetic
variations of both serotonin transporter and corticotrophin
receptor 1 genes lead to the development of MDD (Ressler et al.,
2010).
The trend towards the study of MDD from an epigenetic
approach is increasing with the aid of new available technologies.
These studies allude to environmental stressors that can modify
epigenetically the expressions of susceptible genes, thereby
resulting in the dysfunction of relevant mechanisms in MDD
(Mill and Petronis, 2007; Fass et al., 2014). For example, histone
acetylation and methylation were reported in animal models of
depression (Tsankova et al., 2006; Fuchikami et al., 2009). Similar
mechanisms were proposed to occur in depressed patients
as evidenced by post-mortem brain and serological studies
(Cruceanu et al., 2013; Sun et al., 2013). Moreover, exposure to
early negative experiences was shown to alter methylation of GR
and brain derived neurotropic factor (BDNF; Elliott et al., 2010;
Perroud et al., 2013). Furthermore, epigenetic modifications in
the gene promoter region of BDNF in mood disorder patients
have been shown by several studies to affect the patient’s response
to the treatment received (D’Addario et al., 2012; Lopez et al.,
2013; Tadi´c et al., 2014). These studies suggest the evaluation of
epigenetic changes in BDNF as a potent biomarker for treatment
response in mood disorder patients.
Crosstalk Between the Monoaminergic
and Glutamatergic Systems
Over the past half-century, comprehensive studies concentrating
on the monoamine hypothesis have led to the development of a
number of treatments, whose target is to increase the availability
of monoamines, such as serotonin and norepinephrine (Charney,
1998). Depletion of serotonin is commonly attributed to the
shift from the serotonin pathway to the kynurenine (KYN)
pathway in the catabolism of the essential amino acid tryptophan.
The KYN pathway can be mediated by a variety of cell
types in the body. However, the resulting downstream product
depends on the kind of enzymes that each cell type has for
the processing of tryptophan. In the central nervous system
(CNS), the KYN pathway appears to be mainly mediated by
astrocytes, microglia, and infiltrating macrophages. It is initiated
by activation of indoleamine 2, 3-dioxygenase (IDO) catabolizing
tryptophan into KYN, which can be further converted to
kynurenic acid (KA) or quinolinic acid (QUIN). KA and QUIN
have contrasting roles influencing the glutamatergic system,
the first acting as antagonist and the latter as agonist of the
glutamate N-methyl-D-aspartate receptor (NMDAr; Campbell
et al., 2014). Microglia are the main producers of QUIN in the
brain, whereas astrocytes are the CNS-key cells involved in KA
synthesis. This is explained by the fact that microglia express
kynurenine 3-monooxygenase (KMO), the rate-limiting enzyme
in the production of QUIN. Conversely, astrocytes exclusively
express kynurenine aminotransferases, which are essential in
the conversion of KYN to KA (Guillemin et al., 2001, 2005).
IDO, the initiator of the KYN pathway, has been reported
to be induced by a number of different pro-inflammatory
cytokines, such as interferon-γ (IFN-γ), tumor necrosis factor
α (TNF-α), and interleukin-6 (IL-6). Therefore, the activation
of the KYN pathway is attributed to be cytokine-mediated
(O’Connor et al., 2009a; Kim et al., 2012; Campbell et al.,
2014).
MDD also compromises the glutamatergic system
characterized by the increased activation of NMDAr (Trullas
and Skolnick, 1990). QUIN and glutamate are agonists of
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NMDAr, levels of both being found to be elevated in MDD.
Inflammation can induce the synthesis of QUIN through the
activation of the KYN pathway in microglia and macrophages
in the CNS (Guillemin et al., 2003). QUIN acts not only as
an agonist of NMDAr at the glycine-binding site, but has
also been shown to stimulate the release of glutamate from
neurons, inhibiting its re-uptake by astrocytes (Tavares et al.,
2002, 2005). Furthermore, several studies indicate that QUIN
toxicity can also lead to lipid peroxidation and nitrosative
stress (Behan et al., 1999; Aguilera et al., 2007). On the other
hand, KA is an antagonist of the NMDAr with antioxidant
activity found to induce neuro-protective effects in ischemic
and oxidative stress rodent models (Nozaki and Beal, 1992;
Lugo-Huitrón et al., 2011). Nevertheless, the role of KA in
relation to depression is not yet clear. A recent longitudinal
study of suicide attempters with depression showed that
cerebrospinal fluid (CSF) QUIN levels are increased, while
CSF KA levels are decreased over a 2-year period along with
an increase in IL-6 and worsening of depressive and suicidal
symptoms (Bay-Richter et al., 2015). However, treatment of
the pro-inflammatory cytokine IFN-α in patients with hepatitis
C virus (HCV) was shown to elevate both QUIN and KA
concentrations in the CSF, with only QUIN levels found to
be correlated to depression scores (Raison et al., 2010). IFN-α
therapy has been widely used to treat HCV, though it is reported
to induce depressive and manic symptoms in 30–50% of patients
(Bonaccorso et al., 2002; Constant et al., 2005). Moreover,
studies evaluating the KYN pathway in the periphery have
reported an increased KYN/KA ratio associated with depressive
symptoms in individuals with HCV treated with IFN-α, and
a reduced KA/QUIN ratio in MDD patients compared with
controls (Wichers et al., 2005; Savitz et al., 2015). Of note, new
findings using skeletal muscle-specific peroxisome proliferator-
activated receptor gamma coactivator 1-alpha1 (PGC-1α1)
transgenic mouse model suggest that physical exercise is
beneficial in stress-induced depression due to its modulation of
the KYN pathway. Enhanced PGC-1α1 in the skeletal muscle
stimulated KA synthesis, thus reducing peripheral KYN, which,
contrastingly to KA, can readily cross the BBB (Agudelo
et al., 2014). Interestingly, contrary to the observations in
depression, elevated levels of KA have been associated with the
cognitive deficits in schizophrenic patients (Erhardt et al., 2004;
Linderholm et al., 2012). Augmented inhibition of the NMDAr
by KA appears to cause changes in the glutamatergic system
affecting the dopaminergic neurotransmission, a hallmark
feature of schizophrenia (Wu et al., 2007; Pocivavsek et al.,
2011).
Glial Pathology in Relation to
Neuro-Pathophysiological Alterations
Accumulating evidence suggests that glial pathology is a
prominent feature in MDD. Glial cells are the non-neuronal
cells in the CNS, comprised of astrocytes, microglia and
oligodendrocytes. Human post-mortem studies of mood
disorder patients consistently demonstrate a significant decrease
in the number of glia in the pre-frontal cortex and limbic
structures of the brain (Rajkowska et al., 1999; Cotter et al.,
2001; Bowley et al., 2002; Hamidi et al., 2004; Altshuler et al.,
2010). Moreover, it was reported that glial ablation in the
pre-frontal cortex of mice induces anhedonia, anxiety and
helplessness behavior after exposure to chronic unpredictable
stress procedures. The depressive-like behaviors generated were
assessed by sucrose preference test, novelty suppressed feeding
test, forced swim test, and two-way active avoidance test (Banasr
and Duman, 2008). Furthermore, it was shown in another study
by the same group that exposure to chronic unpredictable stress
can likewise induce glial dysfunction resulting in depressive-like
behavior (Banasr et al., 2010). It was proposed that initial glial
impairment by different stressors leads to neuronal damage in
the progression of the disorder (Rajkowska and Miguel-Hidalgo,
2007).
Astrocytes have multifaceted roles in the CNS, participating
actively in synaptic information transmission, secretion of
synaptogenic molecules, such as BDNF, modulation of the BBB,
mediation of the immune system, and uptake of cytotoxic
molecules from the extracellular space, such as glutamate (Jo
et al., 2014). Astrocytes express the excitatory amino acid
transporters 1 and 2 (EAAT1 and EAAT2), which enables
them to transport glutamate to the intracellular compartment.
Once inside, glutamate is further converted to glutamine by
the enzyme glutamine synthase (Anderson and Swanson, 2000).
Astrocytes also take part in the KYN pathway synthesizing
KA but not QUIN (Guillemin et al., 2001). Accumulating
data from human post-mortem studies of depressed patients
reveal a significant decrease in the number of astroglial cells
and less coverage of blood vessels by astrocytic end-feet
(Johnston-Wilson et al., 2000; Gittins and Harrison, 2011;
Rajkowska et al., 2013). Loss of astrocytes has been demonstrated
by studies reporting decreases of the astrocytic marker glial
fibrillary acidic protein and both enzymes EAAT1 and EAAT2
(Johnston-Wilson et al., 2000; Miguel-Hidalgo et al., 2010;
Gittins and Harrison, 2011). Moreover, morphometric analyses
in the anterior cingulate cortex region of depressed suicides
revealed the presence of hypertrophic astrocytes, indicating
possible astrocytic activation in the area (Torres-Platas et al.,
2011). Furthermore, significantly increased genome-wide DNA
methylation patterns were reported in the pre-frontal cortex
of depressed patients (Nagy et al., 2014). This was found
alongside the down-regulation of astrocytic markers in the
same study, implying possible epigenetic regulations associated
with astrocytic pathology (Nagy et al., 2014). The evidence
reported suggests that in the event of the activation of the KYN
pathway by pro-inflammatory cytokines, without functional
astrocytes, QUIN/KA ratio would be increased. Moreover,
glutamate clearance from the extracellular space would also
result disturbed. Hence, elevated levels of QUIN and glutamate
would promote NMDAr agonism disrupting the glutamatergic
system.
Microglia are professional phagocytes regarded as CNS-
resident immune cells. They are the primary sentinels patrolling
the CNS, alert to any potential harmful event including
pathogen invasion. Moreover, their role is also extended to
debris clearance, trophic support to neurons, and synaptic
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pruning during neurogenesis (Ousman and Kubes, 2012).
In human post-mortem studies, higher microglial activation
was observed in different regions including anterior cingulate
cortex, pre-frontal cortex and hippocampus of depressed
suicides (Steiner et al., 2008; Torres-Platas et al., 2014).
QUIN levels were also found to be dysregulated in different
regions of the brain. Elevated microglial QUIN expression was
reported in the cingulate cortex, whereas a decrease or no
change in microglial QUIN immunoreactivity was observed
in the hippocampus of acutely depressed patients (Steiner
et al., 2011; Busse et al., 2014). Supporting this notion,
it was shown in parallel that chronic unpredictable stress
in mice led to depressive-like behavior such as decrease
in sucrose consumption and social exploration along with
microglial proliferation and activation, ending in subsequent
microglial apoptosis (Kreisel et al., 2014). However, blockade
of microglial initial activation minimized the aforementioned
detrimental effects (Kreisel et al., 2014). Moreover, microglial
cell culture experiments showed that adding IFN-α induced
microglia activation and production of pro-inflammatory
cytokines, such as IL-1β, IL-6 and TNF-α (Zheng et al.,
2015). Furthermore, in another study, IFN-α treated microglia
stimulated the expression of inducible nitric oxide synthase
(iNOS) and secretion of NO, alongside the down-regulation
of heme oxygenase-1 (HO-1), a potent anti-inflammatory and
neuro-protective protein (Lu et al., 2013). Hence, it was
concluded that IFN-α may contribute to the pathogenesis of
depression by triggering inflammation, oxidative stress, and
abrogating anti-inflammatory and neuro-protective responses
(Lu et al., 2013; Zheng et al., 2015). It is therefore suggested
that with the activation of microglia, the secreted pro-
inflammatory cytokines would activate the KYN pathway.
Tryptophan degradation is then shifted to the KYN pathway,
resulting in depletion of monoamines and production of
QUIN, compromising the monoaminergic and glutamatergic
systems.
Oligodendrocytes are the myelin-cell producers in the
CNS enveloping neuronal axons, allowing communication
through action potentials. Among the glia, oligodendrocytes
are particularly vulnerable to stress-related insults (Edgar
and Sibille, 2012). Oligodendrocytic dysfucntion in mood
disorders is evidenced by human post-mortem studies reporting
reduced numbers of oligodendrocytes in the pre-frontal
cortex and amygdala (Hamidi et al., 2004; Uranova et al.,
2004). Perineuronal oligodendrocytes have been identified
in later studies as the subtype of oligodendrocytic cell
affected. Perineuronal oligodendrocytes are non-myelin
producer cells that undergo functional changes following
an injury allowing them to synthesize myelin and possibly
rescue neuronal axons from de-myelination. The loss
of perineuronal oligodendrocytes was reported in the
pre-frontal cortex of mood disorders and schizophrenia
(Vostrikov et al., 2007; Szuchet et al., 2011). Moreover, this
decrease in the number of perineuronal oligodendrocytes
was correlated to cytoarchitectural abnormalities in
genome-wide association analyses (Kim and Webster,
2010).
Despite the differences discussed regarding the type of
glia affected and its state (resting or activated) in the
different neuropsychiatric disorders, the evidence presented
so far suggests that dysfunctional glia play an active role
in the abrogation of the monoaminergic and glutamatergic
neurotransmission systems, contributing to cognitive deficits
and behavioral changes in mood disorders.
Depression as an Inflammatory Disease
The inflammatory hypothesis of depression has gained
momentum since it first appeared two decades ago, proposing
MDD as a cytokine-mediated disorder (Maes et al., 1995; Raison
et al., 2006; Dantzer et al., 2008). An increasing amount of clinical
evidence has shown the presence of augmented levels of pro-
inflammatory markers in the periphery and in the CNS (Maes
et al., 1993; Rotter et al., 2013; Dahl et al., 2014). Moreover, high
rates of comorbidity have been reported between depression and
immune-associated disorders, such as cardiovascular disease,
multiple sclerosis, and autoimmune disorders (Maes et al.,
1993; Bachen et al., 2009; Byatt et al., 2011). Meta-analyses of
studies associating inflammatory markers with MDD reported
significantly higher levels of TNF-α, IL-6, and C-reactive protein
(CRP) in depressed patients (Dowlati et al., 2010; Valkanova
et al., 2013). A recent longitudinal study conducted in England
revealed that children with elevated serum IL-6 and CRP levels
were more at risk to develop depression and psychosis later in
life (Khandaker et al., 2014). Furthermore, several studies report
that cytokine therapy, such as IFN-α, can generate depressive
and manic symptoms in HCV and cancer patients (Bonaccorso
et al., 2002; Capuron et al., 2002; Constant et al., 2005). In one
study, serum levels of TNF-α, IL-6 and soluble IL-2 receptor
were shown to be upregulated after IFN-α treatment (Wichers
et al., 2007). In another study, elevated levels of QUIN and
KA were found in the CSF of patients treated with peripheral
administration of IFN-α (Raison et al., 2010). In further
support of the inflammatory hypothesis of depression, studies
using animal models have demonstrated that administering
lipopolysaccharides (LPS) as well as pro-inflammatory cytokines
induce depressive-like behaviors such as anhedonia, assessed by
sucrose/saccharine preference tests (Yirmiya, 1996; De La Garza,
2005).
It is important to point out that despite this overwhelming
evidence of an association between inflammation and depression,
failed attempts to prove this correlation have also been
reported (Haack et al., 1999; Steptoe et al., 2003). Moreover,
the profile of cytokines in suicidal and non-suicidal patients
is distinct (Kim et al., 2008). Cytokine level changes in
response to antidepressant treatment are also varied (Hannestad
et al., 2011). The heterogeneous results indicate that MDD
is a rather complex disorder with multiple variants involving
the inflammatory response participation to a great extent,
but not in all cases. Nevertheless, cytokines can mediate
several pathways which are crucial in the pathophysiology of
depression. As discussed earlier, pro-inflammatory cytokines
can induce IDO, therefore activating the KYN pathway. This
event can lead to the dysregulation of the monoaminergic and
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glutamatergic neurotransmissions. Moreover, the GR resistance
has been attributed to be cytokine mediated. A number
of cytokines, such as IL-1α, TNF-α and IFN-α, have been
reported to inhibit GR function (Wang et al., 2004; Hu
et al., 2009; Van Bogaert et al., 2011). Without competent
GRs, glucocorticoids such as cortisol cannot exert its anti-
inflammatory effects, thus ending in the exacerbation of
the inflammatory response (Pace et al., 2007). In addition,
GR resistance promotes hyperactivation of the HPA axis
leading to the overproduction of glucocorticoids, hallmark
features of MDD (Anacker et al., 2011). On the other
hand, enhanced activation of the immune system can also
be mediated by inadequate levels of glucocorticoids, resulting
in the development of depressive symptoms (Raison and
Miller, 2003). For example, in the case of atypical depression,
corticotrophin-releasing hormone deficiency, hypoactivity of
the HPA axis, and increased inflammatory response are
often found in these patients (Gold and Chrousos, 2002). It
is proposed that insufficient glucocorticoid signaling, either
by low levels of cortisol or GR resistance, can lead to a
cytokine-mediated onset of depression (Raison and Miller,
2003).
Different hypotheses have been postulated in order to
explain the chronic low-grade inflammatory status in mood
disorders. A number of lifestyle factors have been proposed
to affect the immune status in depressed individuals, such as
non-healthy dietary habits (e.g., high saturated fats, processed
meats, refined carbohydrates, etc.), physical inactivity, smoking
habits, and vitamin D deficiency (Berk et al., 2013). Chronic
psychological stress is a well-studied risk factor suggested to
induce GR resistance and trigger the inflammatory cascade
(Miller et al., 2002; Raison et al., 2006; Cohen et al., 2012). From
the genetic perspective, polymorphisms in the genes PSMB4
(proteasome β4 subunit) and TBX21 (T bet) that result in T-
cell dysfunction, were reported to contribute to the pathology
of MDD (Wong et al., 2008; Berk et al., 2013). A recent
meta-analysis of 28 studies identified significant associations
between depression and infections in Borna disease virus (BDV),
herpes simplex virus-1, varicella zoster virus, Epstein-Bar virus
(EBV), and Chlamydophila trachomatis. Results indicated that
patients with depression are 3.25 times more likely to be
infected with BDV (Wang et al., 2014). However, negative
findings have also been reported (Bennett et al., 2012; Hornig
et al., 2012; Pearce et al., 2012). Despite controversies aroused
concerning direct virus association and mood disorders, several
studies demonstrated that there is a higher risk of developing
mood disorders later in life among individuals who have had
a severe infection (Goodwin, 2011; Benros et al., 2013). In
accordance with these findings, it was previously suggested
that stress could alter the immune system, thereby resulting in
reactivation of persistent viruses in the CNS, further enhancing
the inflammatory reaction (Dietrich et al., 1998). Experimental
evidence demonstrated that rats exposed to stress developed
intestinal permeability and bacterial translocation. LPS from
bacterial translocation activated toll-like receptor 4 (TLR4) in the
brain triggering the neuroinflammatory response (Garate et al.,
2011).
The systemic inflammatory response generates circulating
cytokines and other mediators that can gain access to the
brain through different pathways. The mechanisms involve
cytokine signal propagation, activation of vagal afferents, active
transport across the BBB, and diffusion at sites where the
BBB is leaky or absent. It is important to indicate that this
communication is bi-directional (Maier, 2003). Response within
the CNS is consequently triggered. Microglia and astroglia,
important immune-regulators, become activated and further
enhance the inflammatory response (Biesmans et al., 2013).
In addition, pro-inflammatory cytokines can activate the KYN
pathway in both glial cell types resulting in the dysregulation
of the monoaminergic and glutamatergic systems. On account
of the evidence linking inflammation and depression it was
proposed that depression is a byproduct of the immune systems
in its attempt to fight infection (Raison and Miller, 2013).
Therapeutic Intervention
Among the many types of antidepressants that exist to
date, tricyclic antidepressants, monoamine oxidase inhibitors,
selective serotonin re-uptake inhibitors (SSRIs), and serotonin-
norepinephrine re-uptake inhibitors are some of the most
common types to be prescribed (Anderson et al., 2012; Klomp
et al., 2014). Tricyclic antidepressants were the most widely
prescribed pharmacological agent. However, its supplementation
was found to lead to severer and lethal (overdoses) side
effects compared with the other types of antidepressants
(Boyce and Judd, 1999). Administering monoamine oxidase
inhibitors was found to carry dangerous side effects as well,
and these inhibitors are now used mainly in treatment-resistant
depression (Finberg, 2014). SSRIs have become the first choice
of antidepressants over the last two decades. Although their
efficacy is comparable to the tricyclic antidepressants, the
preferred choice for SSRIs arises from the fact that they are
safer, have better tolerability, and lower rates of treatment
discontinuation (Anderson, 2000). However, response rates are
about 50%, full remission is achieved only in one-third of
patients responding to treatment, and relapse is more often
than not the case (Trivedi et al., 2006). Therefore, the current
drawbacks of presently available antidepressants in a clinical
setting lead to the search for better cost-effective treatments
and the consideration of alternative therapies. For instance,
the triple reuptake inhibitors, which tackle the monoaminergic
system by inhibiting serotonin, norepinephrine, and dopamine
transporters appear to be a promising antidepressant agent
(Chen and Skolnick, 2007). However, their efficacy and side-
effects are currently under investigation (Tran et al., 2012;
Risinger et al., 2014). The use of the NMDAr antagonist
ketamine as an antidepressant has gained some validity in the
last years. Despite its status as a popular abusive drug causing
hallucinations and psychosis, its use in treatment-resistant
depressive patients by targeting the glutamatergic system has
shown faster and greater improvements (Zarate et al., 2006;
Murrough et al., 2013). However, safety and effectiveness of
ketamine usage in the long term needs to be further evaluated
(Rush, 2013).
Frontiers in Cellular Neuroscience | www.frontiersin.org 5 July 2015 | Volume 9 | Article 268
Jo et al. Inflammation and glial pathology in depression
Targeting Inflammation in Depression
On account of increasing evidence pointing towards the
consideration of MDD as a cytokine-mediated disorder, a
number of studies have investigated the implication of current
available agents on the immune response. The outcome
suggests that pharmacological antidepressants can exert anti-
inflammatory effects as a mechanism of action. Studies assessing
fluoxetine and the tricyclic antidepressants clomipramine and
imipramine demonstrated that these agents are capable of
modulating the immune response by inhibiting the activation of
glial cells in cell culture models (Hwang et al., 2008; Obuchowicz
et al., 2014). Moreover, although the meta-analysis of 22 studies
indicated that SSRIs appeared to decrease IL-6 and TNF-α
cytokine levels to some extent, it also demonstrated that despite
the reduced depressive symptoms found in the studies, an overall
effect in the decline of IL-6 and TNF-α after treatment was not
found. Noteworthy, IL-1β levels were found to be significantly
reduced (Hannestad et al., 2011).
Other treatment alternatives aiming to target the chronic
low-grade inflammatory response present in a subgroup of
depressive patients have also been sought. These include
non-steroidal anti-inflammatory drugs (NSAIDs), minocycline,
omega-3 fatty acids, and vitamin D, among others. Usage
of selective cyclooxygenase (COX)-2 and non-selective COX
inhibitors NSAIDs, namely celecoxib and aspirin, to treat MDD
has yielded varied results. A recent meta-analysis of 11 studies
evaluating the use of selective COX-2 or non-selective COX
inhibitors, including seven randomized clinical trials (RCTs)
and four cohort studies, found no overall significant changes
in the response to either type of NSAIDs (Eyre et al., 2015).
However, in the studies evaluated, effectiveness to reduce
depressive symptoms had better outcomes when celecoxib was
used as an add-on therapy (Muller et al., 2006; Akhondzadeh
et al., 2009). On the other hand, the usage of the tetracycline
derivative minocycline to treat mood disorders is currently
undergoing clinical trials (Savitz et al., 2012; Dean et al., 2014).
Minocycline has been suggested to regulate neuroplasticity by
exerting anti-apoptotic, anti-inflammatory and anti-oxidative
properties (Soczynska et al., 2012). Moreover, it has been shown
to modulate the glutamatergic and monoaminergic systems
(O’Connor et al., 2009b; Wixey et al., 2011). Minocycline has
been demonstrated to inhibit activation and proliferation of
microglia, therefore regulating the immune response (Tikka
et al., 2001; Henry et al., 2008). Furthermore, minocycline has
been also shown to facilitate the recovery of sickness behavior
and down-regulate pro-inflammatory cytokines in mice treated
with either LPS or TNF-α (Henry et al., 2008; Zheng et al.,
2015).
In regards to omega-3 fatty acids, although their
supplementation has been reported to exert beneficial effects
in mood disorders (presumably due to its anti-inflammatory
properties), a recent meta-analysis of 13 separate RCTs
demonstrated no significant effect on MDD (Nemets et al., 2002;
Su et al., 2003; Bloch and Hannestad, 2012).
In the case of vitamin D, a meta-analysis of 14 observational
studies falling in the category of case-control, cross-sectional
and cohort demonstrates that low levels of vitamin D are
significantly associated with depression (Anglin et al., 2013).
However, the effectiveness of its supplementation in reducing
depressive symptoms remains controversial (Jaddou et al., 2012;
Kjaergaard et al., 2012). In a recent meta-analysis of seven RCTs,
it was shown that supplementation of vitamin D had no overall
effect on depressive symptoms. Interestingly, the meta-analysis
also points out that better outcomes were achieved with vitamin
D supplementation only in cases where clinically significant
depressed patients participated in the study. In addition, the
largest effect was achieved when vitamin D was administered as
an adjuvant (Shaffer et al., 2014). It is noteworthy to mention
that although vitamin D intake is broadly considered to induce
no adverse effects, overdoses of vitamin D have proven to
cause hypercalcemia (Hathcock et al., 2007). Moreover, a study
conducted in older community-dwelling women reported that
annual high doses of vitamin D (500,000 IU) in a period of 3–5
years increased the risk of falls and fractures, contrary to what
was expected (Sanders et al., 2010).
Vitamin D—A Potential Therapeutic Agent?
Vitamin D is regarded as the sunshine vitamin due to the fact
that the main natural source of vitamin D is UV-mediated in
the epidermal layer of the skin through sunlight stimulation.
UV-light converts 7-dehydrocholesterol to pre-vitamin D3 form,
which is later hydroxylated to the major circulating form
vitamin D3 by the enzyme vitamin D 25-hydroxylase. A final
hydroxylation is conducted by 1-α-hydroxylase generating the
bioactive form 1,25(OH)2D3, also known as calcitriol. However,
other natural sources include cod-liver oil, oily fish, butter,
cream, and egg yolk (Baeke et al., 2010). This light-dependent
source and the fact that vitamin D was demonstrated to act
on the brain, spinal cord and several endocrine tissues led
to suggest a linkage between vitamin D and neuropsychiatric
disorders in individuals less exposed to sunlight (Stumpf and
Privette, 1989). Evidence of vitamin D deficiency was later
shown in seasonal affective disorder patients (Lansdowne and
Provost, 1998). Since then, a number of studies on vitamin D
and its effect on MDD have been conducted, yielding highly
controversial results, as discussed above. Moreover, vitamin D
deficiencies are also reported in the general population (Holick,
2006). Nevertheless, the importance of contemplating vitamin D
as a plausible alternative to treat MDD arises not only from its
cost-effectiveness and low adverse effects, but is also due to its
influence in the immune response.
Vitamin D is a steroid hormone with pleiotropic effects.
Aside from its long-recognized role in regulating calcium
and phosphorous balance, vitamin D can also influence cell
differentiation and proliferation, as well as modulate the immune
system. In the CNS, vitamin D can act as an immune-regulator,
and as stimulator of neurotrophic factors and neurotransmitters
expression (Di Rosa et al., 2011; Eyles et al., 2011; Gezen-Ak
et al., 2011). Vitamin D has two main receptors, membrane-
associated rapid response steroid-binding (MARRS) and vitamin
D receptor (VDR), which are critical for its different regulatory
properties (Khanal and Nemere, 2007; Meyer et al., 2010).
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MARRS is a membrane receptor that when bound to vitamin
D induces rapid non-genomic responses, such as modulation
of calcium concentrations and activity of protein kinase C
(Khanal and Nemere, 2007). VDR, on the other hand, is a
transcription factor that regulates the expression of multiple
genes and is responsible for the non-classical responses of
vitamin D (Meyer et al., 2010). Upon binding to vitamin D,
VDR translocates to the nucleus and heterodimerizes with
the retinoid X receptor (RXR). Subsequently, the VDR-RXR
complex formed binds to vitamin D responsive elements in
the DNA to activate or repress the expression of vitamin D
target genes (Fetahu et al., 2014). Moreover, the VDR gene
has large cytosine/guanine dinucleotide (CpG) repeats at the
promoter region that are susceptible to epigenetic modifications.
Conversely, VDR can also modulate the epigenome, inducing
DNA methylation and chromatin modulation (Fetahu et al.,
2014).
VDR is expressed in more than 38 types of cells, including
immune cells (e.g., monocytes, dendritic cells, activated B
and T cells) and CNS cells (e.g., neurons, astrocytes, and
microglia; Di Rosa et al., 2011; Cui et al., 2013; Smolders
et al., 2013). VDR activation was reported to regulate the
innate immune response by inducing tolerogenic dendritic cells,
inhibiting type 1 T helper (Th1) cell responses, as well as
downregulating TLR2, TLR4, and TLR9, inducing decreased
expressions of IL-6 (Dickie et al., 2010). Studies with neurons
also showed that VDR can regulate the expressions of nerve
growth factor and iNOS (Gezen-Ak et al., 2011; Dursun et al.,
2013). In addition, the VDR gene has been reported to be
associated with viral and bacterial infections. In one study,
Epstein-Barr virus nuclear antigen 3 (EBNA-3; produced by
EBV) was demonstrated to bind to VDR inducing blockage
of VDR-dependent genes, thus protecting cells from VDR-
induced growth arrest and/or apoptosis (Yenamandra et al.,
2010). Another study showed downregulation of VDR expression
in monocytes by Borrelia burgdorferi infection (Salazar et al.,
2009). In addition, human immunodeficiency virus (HIV)
was proved to downregulate VDR expression by inducing
its hypermethylation in T cells. This event resulted in the
activation of the renin angiotensin system and generation
of reactive oxidative species, consequently leading to T cell
apoptosis (Chandel et al., 2013). Moreover, vitamin D elicits
the expression of the anti-microbial peptides cathelicidin and
defensin, important for counteracting infection (Gombart,
2009).
Despite the substantial amount of evidence linking VDR
and the immune response, its role in the regulation of
the inflammatory response in mood disorders remains to
be elucidated. Only two studies to date have reported an
association between VDR gene variant and susceptibility to
develop depressive symptoms in old age (Kuningas et al.,
2009; Glocke et al., 2013). Moreover, studies evaluating
the relationship of vitamin D and the cytokine network
in mood disorders fall short of expectations. In a recent
study, it was reported that suicide attempters had significantly
lower levels of vitamin D and higher levels of the pro-
inflammatory cytokine IL-1β circulating the blood in comparison
to non-suicidal depressed participants and healthy controls. In
another study evaluating obese women with polycystic ovary
syndrome, vitamin D deficiency was found to be associated
with higher depressive symptoms and higher CRP, independent
of polycystic ovary syndrome presence (Moran et al., 2015).
Furthermore, studies regarding vitamin D immuno-modulatory
effects on microglia and astrocytes in depression models
are limited in spite of the considerable amount of evidence
showing the relevance of these glial cells in the mediation
of the CNS immune system. Microarray analysis of primary
mixed CNS glia cultures showed that when challenged by
a mixed group of Th1 or Th2 cytokines (pro-inflammatory
and anti-inflammatory cytokines, respectively) the dopaminergic
receptor and enzymes involved in vitamin D metabolism were
affected. The expression of 25-hydroxylase (CPY27B1), which
generates calcitriol, became upregulated when stimulated with
pro-inflammatory cytokines of the Th1 group, whereas the
expression of 24-hydroxylase (CPY24A1), the enzyme that
catabolizes calcitriol, became downregulated when stimulated
with anti-inflammatory cytokines of the Th2 group (Lisak
et al., 2009). In line with these results are findings from
another study, in which the addition of IFN-γ and TNF
to primary human microglia and astrocytic cultures showed
upregulation of CYP27B1 mRNA expression, which was reduced
in the presence of active vitamin D (Smolders et al., 2013).
In a recent report, vitamin D deficient microglia cultures
stimulated by TLR agonists showed a decrease of TNF-α
and IL-6. Moreover, lower phagocytosis and intracellular
killing rates of Escherichia coli were also observed (Djukic
et al., 2014). In an Alzheimer’s disease model, human
primary microglia triggered by β-amyloid appear to influence
the expression of various inflammatory-related proteins, as
well as the upregulation of IDO and VDR (Walker et al.,
2006).
Hence, the potential role of VDR influencing the peripheral
and/or CNS immune response makes it an attractive target
of study in the cytokine-mediated model of MDD (Figure 1).
In addition, VDR susceptibility to epigenetic changes and
likewise its role as epigenetic modulator raises the possibility of
considering VDR as a potential biomarker inMDD. For instance,
novel biomarkers, such as BDNF promoter methylation, are
found to predict mood disorder patient’s response to treatment
in some studies (D’Addario et al., 2012; Lopez et al., 2013;
Tadi´c et al., 2014). Moreover, relations of VDR epigenetic
modifications are already being widely investigated in cancer
studies (Fetahu et al., 2014).
It is noteworthy that vitamin D and omega-3 fatty acids
also take part in pathways other than the inflammatory
network influencing the development of neuropsychiatric
illnesses. It was proposed that deficiencies of vitamin D
and omega-3 fatty acids in the brain affect serotonin-related
mechanisms (Patrick and Ames, 2015). The heterodimer
VDR-RXR stimulates serotonin synthesis by activating the
tryptophan hydroxylase-2 transcription (Patrick and Ames,
2014). In addition, the omega-3 fatty acid eicosapentaenoic
acid was suggested to facilitate serotonin release from neurons
(Patrick and Ames, 2015). Moreover, omega-3 fatty acids were
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FIGURE 1 | Vitamin D and its receptor (VDR) in the cytokine-mediated
onset of depression. (A) Stress and/or infection activate the inflammatory
response resulting in inflammatory cytokines production. These cytokines can
trigger the kynurenine (KYN) pathway by stimulating indoleamine 2,
3-dioxygenase (IDO). Therefore, tryptophan enters the KYN pathway instead
of the serotonergic pathway, resulting in the depletion of monoamines. Once
the KYN pathway is triggered, kynurenic acid (KA) in astrocytes and
quinolinic acid (QUIN) in microglia are synthesized. QUIN contributes to the
activation of N-methyl-D-aspartate receptor (NMDAr) itself and by inhibiting
glutamate re-uptake, resulting in excessive extracellular glutamate, inducing
further NMDAr agonism. Excessive NMDAr activation leads to the disruption
of the glutamatergic system, a key pathological feature in mood disorders.
(B) The binding of vitamin D to VDR in a number of immune cells (e.g.,
macrophages, neutrophils, dendritic cells, B cells, T cells, astrocytes and
microglia) leads to attenuation of the inflammatory response and stimulation
of anti-microbial peptides production, potentially ameliorating symptoms of
mood disorders. However, certain pathogens can also block or modulate
epigenetic VDR activity.
also found as a low-affinity ligand of VDR (Jurutka et al.,
2007).
Conclusions and Future Directions
Depression constitutes a distressing health concern topic. In
the last decades, the importance of treating MDD has been
accentuated, attracting public interest due to its increasing
worldwide prevalence, particularly in high-income countries,
threatening to become the leading cause of global disability.
Moreover, currently available pharmacological antidepressants
do not achieve desired results, producing severe side effects with
high relapse rates. Increasing evidence suggests the involvement
of the immune response. Cytokine-induced sickness behavior
is proposed to culminate in MDD by promoting the activation
of the KYN pathway and GR resistance, hence compromising
the monoaminergic and glutamatergic neurotransmission along
with the HPA axis hyperactivation. Therefore, new alternative
options targeting the inflammatory response in mood disorders
are being tested. Vitamin D appears to be a plausible candidate
although current results from RCTs do not provide sufficient
evidence to encourage its supplementation in MDD. It is,
however, arguable that the intervention of vitamin D-VDR in
different molecular mechanisms affecting the immune system
is not fully understood. Research directed towards investigating
the role of VDR in regulating the periphery and CNS immune
response in relation to mood disorders is suggested. Moreover,
another important issue raised in this review is the active
participation of glial cells in the dysregulation of relevant
mechanisms in the pathology of depression. Microglia and
astrocytes are important CNS-immune mediators. However,
interactions between VDR and glia have hardly been studied.
In view of the global importance of MDD and
the gaps in knowledge that still exist concerning its
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pathophysiology, further pursuit of knowledge in regards
to the glio-pathogenesis of the inflammatory system
activation aiming to find better treatment options is highly
warranted.
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